Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutations
Authors:
- Viviane C LonguiniVLViviane C Longuini
- Delmar M LourençoDelmar M Lourenço
- Tomoko SekiyaTSTomoko Sekiya
- Osorio MeirellesOMOsorio Meirelles
- Tatiana D GoncalvesTGTatiana D Goncalves
- Flavia L CoutinhoFCFlavia L Coutinho
- Guilherme FranciscoGFGuilherme Francisco
- Luciana H OsakiLuciana H Osaki
- Roger ChammasRoger Chammas
- Venancio A F AlvesVAVenancio A F Alves
- Sheila A C SiqueiraSSSheila A C Siqueira
- David SchlesingerDSDavid Schlesinger
- 1 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 171 (3) , 335-342
Abstract
Objective: To date, no evidence of robust genotype–phenotype correlation or disease modifiers for multiple endocrine neoplasia type 1 (MEN1) syndrome has been described, leaving the highly variable clinical presentation of patients unaccounted for.Design: As the CDKN1B (p27) gene causes MEN4 syndrome and it is transcriptionally regulated by the product of the MEN1 gene (menin), we sought to analyze whether p27 influences the phenotype of MEN1-mutated patients. The cohort consisted of 100 patients carrying germline MEN1 gene mutations and 855 population-matched control individuals.Methods: Genotyping of the coding p27 c.326T>G (V109G) variant was performed by sequencing and restriction site digestion, and the genotypes were associated with clinical parameters by calculating odds ratios (ORs) and their 95% CIs using logistic regression.Results: There were significant differences in p27 V109G allele frequencies between controls and MEN1-mutated patients (OR=2.55, P=0.019, CI=1.013–5.76). Among patients who are ≥30 years old carrying truncating MEN1 mutations, the T allele was strongly associated with susceptibility to tumors in multiple glands (three to four glands affected vs one to two glands affected; OR=18.33; P=0.002, CI=2.88–16.41). This finding remained significant after the Bonferroni's multiple testing correction, indicating a robust association. No correlations were observed with the development of MEN1-related tumors such as hyperparathyroidism, pituitary adenomas, and enteropancreatic and adrenocortical tumors.Conclusions: Our study suggests that the p27 tumor suppressor gene acts as a disease modifier for the MEN1 syndrome associated with MEN1 germline mutations. If confirmed in independent patient cohorts, this finding could facilitate the management of this clinically complex disease.Keywords
This publication has 33 references indexed in Scilit:
- Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcomeClinical Endocrinology, 2009
- Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the geneHuman Mutation, 2007
- Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelinesJournal of Internal Medicine, 2004
- Clinical Genetic Testing and Early Surgical Intervention in Patients With Multiple Endocrine Neoplasia Type 1 (MEN 1)Annals of Surgery, 2004
- CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2The Journal of Clinical Endocrinology & Metabolism, 2001
- Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1Human Molecular Genetics, 1997
- Positional Cloning of the Gene for Multiple Endocrine Neoplasia-Type 1Science, 1997
- Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinomaNature, 1988
- Endocrine adenomatosis and peptic ulcer in a large kindredThe American Journal of Medicine, 1963
- Genetic aspects of adenomatosis of endocrine glandsThe American Journal of Medicine, 1954